If you were paying attention to my “Take It to the Bank” recommendation last week, you’re probably pretty happy right now – it’s already gone up approximately 9% since last week’s post. There’s still plenty of potential upside there, too, so don’t miss out on that.

Today, we’re going to shift gears a little and look at the pharmaceutical industry. Whenever you have a market downturn like we experienced during the banking crisis, it opens up opportunities to pick up great companies on the cheap before markets push back up again. And with the bulls working so hard to keep the S&P above 4000 and sustain last week’s rally, this is the perfect time to go looking.

And it just so happens that one of the biggest names in this space is available at a premium. We’re talking about a company that brings in $100+ billion a year in revenue, maintains a 31.25% profit margin, and is still maintaining a trailing 12-month (TTM) earnings growth over 35%. It boasts one of the strongest balance sheets in its sector, period.

Better yet, it’s currently trading at an ideal price point. Thanks to recent selloffs, share price is consolidating around $41, at just a 7.5 trailing P/E ratio (in other words, super cheap), but I could easily see it jumping another 35% within a year, back up to its December 2022 highs.

And while you’re waiting for that appreciation, you can enjoy a handsome dividend yield – about 4% as of this writing, with plenty of cash on hand to ensure consistent payouts.

For me, there’s absolutely no better place to put $100 (or however much capital you have to work with) right now.

For the ticker, just watch the video below:

We’ll be back next week with another opportunity to “take it to the bank.” See you then!

— Shah Gilani

We Could Be Less Than 3 Months Out from an AI Superevent [sponsor]
According to one of the world's top AI scientists, there's a major event coming as soon as three months from today that could cause expensive tech stocks like Microsoft, Google, and NVIDIA to double or triple in price in the months ahead... but whatever you do, don't go all in on big tech before you have all the details. Click here.

Source: Total Wealth